Stryker stock: 31.42 price-to-earnings ratio puts Stryker stock above peers

Published on 10/20/2026 at 17:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Stryker's next results are due October 29, 2026 after the close. Stryker stock costs EUR 269.40 on October 20, 2026, up 1.28 percent versus Xetra close.

Valuation and trading facts

Stryker's price-to-earnings ratio exceeds Medtronic's 23.19 and Boston Scientific's 18.65 on October 20, 2026.
Stryker's next quarterly results are scheduled for October 29, 2026, after the close.
Stryker stock costs EUR 269.40 at Lang & Schwarz on October 20, 2026 at 5:06 p.m. CEST, 1.28 percent above the Xetra close of October 19, 2026.

Makrofoto einer polierten Titan-Implantatoberfläche mit feiner Textur und Lichtreflexen — Makroaufnahme einer Titan-Implantatoberfläche zeigt Präzisionsfertigung, typisch für Produkte von Stryker Corp. US8636671013, Illustration mit AI erstellt.

Stryker Corp. (ISIN US8636671013) carried a price-to-earnings ratio of 31.42 on October 20, 2026, above Medtronic's 23.19 and Boston Scientific's 18.65. The next quarterly results are due October 29, 2026, after the close, Gekko reports. Stryker was trading at EUR 269.40 at Lang & Schwarz on October 20, 2026 at 5:06 p.m. CEST, up 1.28 percent versus the Xetra close of October 19, 2026 at EUR 266.00.

Valuation stands above peers

The valuation gap is visible across large medical-device companies. Stryker's 31.42 multiple exceeds Medtronic's 23.19 and Boston Scientific's 18.65, all dated October 20, 2026. The comparison places Stryker at the higher end of this small peer set, while the current euro quotation remains below the level used for its US-listed shares.

Gekko lists Stryker on the New York Stock Exchange under ticker SYK and describes the company as a medical-technology supplier spanning orthopaedics, spine, surgical equipment and neurotechnology.

Trading range gives the daily frame

The Xetra quote covered EUR 265.00 to EUR 270.30 on October 20, 2026, with volume of 176 shares at 5:13 p.m. CEST. The Lang & Schwarz price of EUR 269.40 sat inside that range, while the 1.28 percent gain against the October 19 Xetra close kept the move below the 2.00 percent threshold that would make the daily change the main story.

Results date remains the next marker

The October 29 reporting date gives the valuation comparison a near-term test. The published schedule places the release after the US market close, so the next report will provide the next dated operating checkpoint for revenue, earnings and management guidance. Stryker's latest reported second-quarter revenue was USD 6.59 billion, while adjusted earnings per share reached USD 3.69 in the period ended June 30, 2026.

On October 12, 2026, Stryker and CMR Surgical announced a strategic alliance to advance robotic-assisted surgery, according to Stryker. The company said the cooperation combines CMR's robotics platform with Stryker's commercial reach.

Stryker stock after the Xetra close

For investors, the key contrast is a 31.42 price-to-earnings ratio against lower peer multiples, alongside a 1.28 percent daily gain and a scheduled October 29 report.

The further course of trading is shown by the continuously updated real-time quote of Stryker stock.